Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Phase 1  





2 Phase 2  



2.1  Cytotoxic protein pathway  





2.2  Fas ligand pathway  







3 References  














CTL-mediated cytotoxicity







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Within the scientific discipline of toxicology, Cytotoxic T lymphocytes (CTLs) are generated by immune activation of cytotoxic T cells (Tc cells). They are generally CD8+, which makes them MHC class I restricted. CTLs are able to eliminate most cells in the body since most nucleated cells express class I MHC molecules. The CTL-mediated immune system can be divided into two phases. In the first phase, functional effector CTLs are generated from naive Tc cells through activation and differentiation. In the second phase, affector CTLs destroy target cells by recognizing the antigen-MHC class I complex.

Phase 1

[edit]

In phase one, effector CTLs are generated from CTL precursors. The CTL precursors include naive Tc cells since they are incapable of killing target cells. After a precursor cell has been activated, it can then differentiate into a functional CTL with cytotoxic activity. There are three sequential signals that are required to complete this process.

First, there is TCR recognition of the peptide-MHC class I complex. This step allows the cell to become licensed to an antigen-presenting cell.

Second, a costimulatory signal is transmitted by the interaction between CD28 and B7 of the precursor cell and the licensed antigen-presenting cell.

Last, a signal is induced by the interaction between IL-2 and the high-affinity IL-2 receptor. This results in proliferation and differentiation of the antigen-activated precursor cell into a functional effector CTL.

Phase 2

[edit]

In phase two, the now functional effector CTLs destroy the target cells. This can be done in two ways. These pathways are the cytotoxic protein pathway and the Fas ligand pathway. Apoptosis is the primary mechanism for both of these pathways.

Cytotoxic protein pathway

[edit]

One pathway is the cytotoxic protein pathway. In this pathway perforins and granzymes are taken up by the target cell. In this pathway, the perforins facilitate the entry of granule contents into the cell. The granzymes then activate the endogenous apoptosis pathway, which induces cell death without necrosis. This leaves packages of fragmented DNA material from the target cell for the macrophages to dispose of.

Fas ligand pathway

[edit]

The other pathway is the Fas ligand pathway. In this pathway, a Fas ligand (FasL) on the CTL binds to Fas receptor (FasR) on the target cell. This pathway is independent of granzymes. Instead it involves Interleukin-1β converting enzyme (ICE; also known as Caspase 1) activation, which is similar to granzyme B. This ultimately leads to DNA fragmentation.

References

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=CTL-mediated_cytotoxicity&oldid=1231793647"

Category: 
Toxicology
Hidden categories: 
Articles needing additional references from June 2024
All articles needing additional references
 



This page was last edited on 30 June 2024, at 08:59 (UTC).

Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



Privacy policy

About Wikipedia

Disclaimers

Contact Wikipedia

Code of Conduct

Developers

Statistics

Cookie statement

Mobile view



Wikimedia Foundation
Powered by MediaWiki